Healthcare
Viveve Medical, Inc.(VIVE)
Live Price
Offline$0.0002
+0.00% today
1Y Change
-80.00%
Window
Jun 23, 2025 โ Jun 17, 2026
- Market Cap
- โ
- Revenue Growth
- +17.3%
- EPS Growth
- +84.0%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Viveve Medical, Inc. (VIVE) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 80.0% across the available one-year price window (Jun 23, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of +17.3%, EPS growth of +84.0%, a dividend yield of 0.0%. What stands out right now is revenue +17.3%, EPS +84.0%, free cash flow +16.7% with operating margin -335.4% and ROIC -99.8%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines VIVE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+17.3% vs +7.6% peer median
Operating Margin
Below sector median
-335.4% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 15, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +17.3% and EPS at +84.0%, with operating margin around -335.4%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -30.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 15, 2026 | โ | +0.0% | +0.0% | +0.0% |
2026 Mar 20, 2026 | โ | +0.0% | +0.0% | +0.0% |
2024 Oct 3, 2024 | โ | -90.0% | -90.0% | -90.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VIVE
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
VIVE Max Drawdown
-90.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for VIVE and SPY.
Company Overview
Viveve Medical, Inc.
Other OTC
Viveve Medical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The company offers Viveve System comprises of the radiofrequency generator, reusable handpiece, and treatment tip, as well as cryogen canister and other consumable components. It markets its products through sales employees and distributors in the United States, Canada, the Asia Pacific, Europe, the Middle East, Latin America, and internationally. Viveve Medical, Inc. was founded in 2005 and is headquartered in Englewood, Colorado.
- Leadership
- Martin Kerber
- IPO Date
- May 3, 2010
- Employees
- 47
- Street Address
- Building B
- Mailing
- Englewood, CO, 80112
- Region
- Englewood, CO, US
- Reporting Currency
- USD
- Investor Line
- 720 696 8100
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 0.7
- Price/Sales
- 0.0
- Price/Book
- 0.0
Growth
- Revenue
- +17.3%
- EPS
- +84.0%
- Free Cash Flow
- +16.7%
Profitability
- Gross Margin
- 9.6%
- Operating Margin
- -335.4%
- Net Margin
- -342.8%
- ROE
- -199.9%
- ROIC
- -99.8%
Balance Sheet
- Debt/Equity
- 0.36
- Current Ratio
- 4.91
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.